Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21672237 | 0.85 | PDCD1 (0.40) | HTR2AHTR2CHTR2BL3MBTL1 | |
| SCHEMBL24920236 | 0.83 | — | — | |
| SCHEMBL5644866 | 0.81 | CSNK2A1 (0.31) | — | |
| SCHEMBL2730012 | 0.75 | HAVCR2 (0.36) | HTR2C | |
| SCHEMBL22487889 | 0.75 | HRH4 (0.35) | L3MBTL1 | |
| SCHEMBL14008901 | 0.75 | HRH4 (0.38) | L3MBTL1 | |
| Hydrochloric Acid SCHEMBL2259171 | 0.73 | HAVCR2 (0.35) | — | |
| SCHEMBL19012501 | 0.73 | HRH4 (0.37) | L3MBTL1 | |
| Hydrochloric Acid SCHEMBL210189 | 0.73 | HAVCR2 (0.35) | — | |
| SCHEMBL19033524 | 0.70 | HTR2C (0.30) | HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787793-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787793-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230014651-A1 | BIPHENYL FLUORINE DOUBLE BOND DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-01-19 | — | — | US | disclosed |
| US-20220194931-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2022-06-23 | — | — | US | disclosed |
| US-11339149-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2022-05-24 | — | — | US | disclosed |
| US-20210107900-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2021-04-15 | — | — | US | disclosed |
| US-10800768-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2020-10-13 | — | — | US | disclosed |
| US-20190225601-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2019-07-25 | — | — | US | disclosed |
| US-10308644-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180179197-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| US-20180179197-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339149-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | HTR2A 2867/4885HTR2C 2942/4885HTR2B 3446/4885 |
| US-20210107900-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | HTR2A 2867/4885HTR2C 2942/4885HTR2B 3446/4885 |
| US-20190225601-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | HTR2A 2867/4885HTR2C 2942/4885HTR2B 3446/4885 |
| US-20220194931-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | HTR2A 2867/4885HTR2C 2942/4885HTR2B 3446/4885 |
| US-11787793-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | HTR2A 2867/4885HTR2C 2942/4885HTR2B 3446/4885 |
| US-10308644-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | HTR2A 2867/4885HTR2C 2942/4885HTR2B 3446/4885 |
| US-10800768-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | HTR2A 2867/4885HTR2C 2942/4885HTR2B 3446/4885 |
| US-20180179197-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | HTR2A 2867/4885HTR2C 2942/4885HTR2B 3446/4885 |
| US-20230014651-A1 | BIPHENYL FLUORINE DOUBLE BOND DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | PDCD1, CD274, PDCD1LG2 | HTR2A 3763/4885HTR2C 3227/4885HTR2B 3568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.